194 related articles for article (PubMed ID: 34039907)
1. Case Report: Pentosan Polysulfate Sodium Maculopathy Originally Diagnosed as Pattern Macular Dystrophy.
Case AW; Anderson MJ; Sayomac LE
Optom Vis Sci; 2021 Jun; 98(6):552-556. PubMed ID: 34039907
[TBL] [Abstract][Full Text] [Related]
2. Pentosan Polysulfate Maculopathy versus Inherited Macular Dystrophies: Comparative Assessment with Multimodal Imaging.
Barnes AC; Hanif AM; Jain N
Ophthalmol Retina; 2020 Dec; 4(12):1196-1201. PubMed ID: 32446908
[TBL] [Abstract][Full Text] [Related]
3. Age-Related Macular Degeneration Masquerade: A Review of Pentosan Polysulfate Maculopathy and Implications for Clinical Practice.
Mukhopadhyay C; Boyce TM; Gehrs KM; Folk JC; Mullins RF; Luo Y; Kreder K; Sohn EH
Asia Pac J Ophthalmol (Phila); 2022 Mar-Apr 01; 11(2):100-110. PubMed ID: 35533330
[TBL] [Abstract][Full Text] [Related]
4. PENTOSAN POLYSULFATE SODIUM-INDUCED PIGMENTARY MACULOPATHY WITH NONLEAKING CYSTOID MACULAR EDEMA SUCCESSFULLY TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
De Larochellière E; Bourgault S
Retin Cases Brief Rep; 2022 Jul; 16(4):482-485. PubMed ID: 32541441
[TBL] [Abstract][Full Text] [Related]
5. Pentosan polysulfate maculopathy.
Lindeke-Myers A; Hanif AM; Jain N
Surv Ophthalmol; 2022; 67(1):83-96. PubMed ID: 34000253
[TBL] [Abstract][Full Text] [Related]
6. Expanded Clinical Spectrum of Pentosan Polysulfate Maculopathy: A Macula Society Collaborative Study.
Jain N; Liao A; Garg SJ; Patel SN; Wykoff CC; Yu HJ; London NJS; Khurana RN; Zacks DN;
Ophthalmol Retina; 2022 Mar; 6(3):219-227. PubMed ID: 34298229
[TBL] [Abstract][Full Text] [Related]
7. RAPID PENTOSAN POLYSULFATE SODIUM MACULOPATHY PROGRESSION.
Somisetty S; Santina A; Abraham N; Lu A; Morales VR; Sarraf D
Retin Cases Brief Rep; 2023 Nov; 17(6):660-663. PubMed ID: 35385434
[TBL] [Abstract][Full Text] [Related]
8. Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium.
Pearce WA; Chen R; Jain N
Ophthalmology; 2018 Nov; 125(11):1793-1802. PubMed ID: 29801663
[TBL] [Abstract][Full Text] [Related]
9. Type 3 macular neovascularization in a patient with pentosan polysulfate maculopathy.
Bousquet E; Lee BA; Santina A; Sadda S; Sarraf D
Am J Ophthalmol Case Rep; 2023 Mar; 29():101771. PubMed ID: 36561881
[TBL] [Abstract][Full Text] [Related]
10. Association Between Pentosan Polysulfate Sodium and Retinal Disorders.
McGwin G; MacLennan P; Owsley C
JAMA Ophthalmol; 2022 Jan; 140(1):37-42. PubMed ID: 34792558
[TBL] [Abstract][Full Text] [Related]
11. Pentosan-associated maculopathy: prevalence, screening guidelines, and spectrum of findings based on prospective multimodal analysis.
Wang D; Au A; Gunnemann F; Hilely A; Scharf J; Tran K; Sun M; Kim JH; Sarraf D
Can J Ophthalmol; 2020 Apr; 55(2):116-125. PubMed ID: 31973791
[TBL] [Abstract][Full Text] [Related]
12. Pentosan polysulfate and a pigmentary maculopathy: causation versus correlation?
Proctor JG
Can J Urol; 2023 Dec; 30(6):11732-11739. PubMed ID: 38104330
[TBL] [Abstract][Full Text] [Related]
13. Cystoid Macular Edema Arising 10 Years After Cessation of Pentosan Polysulfate Sodium Successfully Treated With Bevacizumab.
Szelog JT; Shah NS; Camejo MD
J Vitreoretin Dis; 2023; 7(1):83-86. PubMed ID: 37008392
[TBL] [Abstract][Full Text] [Related]
14. Progressive Maculopathy After Discontinuation of Pentosan Polysulfate Sodium.
Huckfeldt RM; Vavvas DG
Ophthalmic Surg Lasers Imaging Retina; 2019 Oct; 50(10):656-659. PubMed ID: 31671200
[TBL] [Abstract][Full Text] [Related]
15. Pentosan Polysulfate Maculopathy: Prevalence, Spectrum of Disease, and Choroidal Imaging Analysis Based on Prospective Screening.
Wang D; Velaga SB; Grondin C; Au A; Nittala M; Chhablani J; Vupparaboina KK; Gunnemann F; Jung J; Kim JH; Ip M; Sadda S; Sarraf D
Am J Ophthalmol; 2021 Jul; 227():125-138. PubMed ID: 33651989
[TBL] [Abstract][Full Text] [Related]
16. NINE-YEAR PROGRESSION OF PENTOSAN MACULOPATHY WITH MULTIMODAL RETINAL IMAGING.
Santina A; Fogel-Levin M; Abraham N; Sarraf D
Retin Cases Brief Rep; 2023 Nov; 17(6):664-667. PubMed ID: 35344532
[TBL] [Abstract][Full Text] [Related]
17. Pentosan polysulfate maculopathy versus age-related macular degeneration: comparative assessment with multimodal imaging.
Christiansen JS; Barnes AC; Berry DE; Jain N
Can J Ophthalmol; 2022 Feb; 57(1):16-22. PubMed ID: 33722504
[TBL] [Abstract][Full Text] [Related]
18. Pentosan Polysulfate Sodium-Associated Maculopathy: Early Detection Using OCT Angiography and Choriocapillaris Flow Deficit Analysis.
Fogel Levin M; Santina A; Corradetti G; Au A; Lu A; Abraham N; Somisetty S; Romero Morales V; Wong A; Sadda S; Sarraf D
Am J Ophthalmol; 2022 Dec; 244():38-47. PubMed ID: 35901995
[TBL] [Abstract][Full Text] [Related]
19. PENTOSAN POLYSULFATE SODIUM (ELMIRON) MACULOPATHY: A Genetic Perspective.
Kalaw FGP; Ignacio JCI; Wu CY; Ferreyra H; Nudleman E; Baxter SL; Freeman WR; Borooah S
Retina; 2023 Jul; 43(7):1174-1181. PubMed ID: 36996461
[TBL] [Abstract][Full Text] [Related]
20. Disease Course in Patients With Pentosan Polysulfate Sodium-Associated Maculopathy After Drug Cessation.
Shah R; Simonett JM; Lyons RJ; Rao RC; Pennesi ME; Jain N
JAMA Ophthalmol; 2020 Aug; 138(8):894-900. PubMed ID: 32644147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
